Class information for:
Level 1: ABIRATERONE//ENZALUTAMIDE//CASTRATION RESISTANT PROSTATE CANCER

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
1208 2691 37.9 79%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
157 21931 BENIGN PROSTATIC HYPERPLASIA//PROSTATE CANCER//PROSTATE

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 ABIRATERONE Author keyword 228 81% 5% 137
2 ENZALUTAMIDE Author keyword 195 84% 4% 106
3 CASTRATION RESISTANT PROSTATE CANCER Author keyword 190 55% 9% 238
4 CABAZITAXEL Author keyword 176 77% 4% 119
5 ABIRATERONE ACETATE Author keyword 169 87% 3% 82
6 SIPULEUCEL T Author keyword 132 85% 3% 69
7 METASTATIC CASTRATION RESISTANT PROSTATE CANCER Author keyword 75 76% 2% 53
8 HORMONE REFRACTORY PROSTATE CANCER Author keyword 71 49% 4% 106
9 HORMONE REFRACTORY Author keyword 52 46% 3% 84
10 CASTRATION RESISTANT Author keyword 45 54% 2% 57

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 ABIRATERONE 228 81% 5% 137 Search ABIRATERONE Search ABIRATERONE
2 ENZALUTAMIDE 195 84% 4% 106 Search ENZALUTAMIDE Search ENZALUTAMIDE
3 CASTRATION RESISTANT PROSTATE CANCER 190 55% 9% 238 Search CASTRATION+RESISTANT+PROSTATE+CANCER Search CASTRATION+RESISTANT+PROSTATE+CANCER
4 CABAZITAXEL 176 77% 4% 119 Search CABAZITAXEL Search CABAZITAXEL
5 ABIRATERONE ACETATE 169 87% 3% 82 Search ABIRATERONE+ACETATE Search ABIRATERONE+ACETATE
6 SIPULEUCEL T 132 85% 3% 69 Search SIPULEUCEL+T Search SIPULEUCEL+T
7 METASTATIC CASTRATION RESISTANT PROSTATE CANCER 75 76% 2% 53 Search METASTATIC+CASTRATION+RESISTANT+PROSTATE+CANCER Search METASTATIC+CASTRATION+RESISTANT+PROSTATE+CANCER
8 HORMONE REFRACTORY PROSTATE CANCER 71 49% 4% 106 Search HORMONE+REFRACTORY+PROSTATE+CANCER Search HORMONE+REFRACTORY+PROSTATE+CANCER
9 HORMONE REFRACTORY 52 46% 3% 84 Search HORMONE+REFRACTORY Search HORMONE+REFRACTORY
10 CASTRATION RESISTANT 45 54% 2% 57 Search CASTRATION+RESISTANT Search CASTRATION+RESISTANT

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 MITOXANTRONE PLUS PREDNISONE 511 68% 17% 445
2 ABIRATERONE ACETATE 218 66% 8% 202
3 INCREASED SURVIVAL 218 58% 9% 254
4 ANTIANDROGEN WITHDRAWAL 169 80% 4% 106
5 ESTRAMUSTINE 120 51% 6% 169
6 MITOXANTRONE 105 22% 16% 421
7 PLUS PREDNISONE 103 67% 3% 94
8 ESTRAMUSTINE PHOSPHATE 97 58% 4% 111
9 ABIRATERONE 95 56% 4% 115
10 ORAL ESTRAMUSTINE PHOSPHATE 93 83% 2% 53

Journals


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 CLINICAL GENITOURINARY CANCER 6 11% 2% 55

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects 2015 6 151 38%
Enzalutamide After Docetaxel and Abiraterone Acetate Treatment in Prostate Cancer: A Pooled Analysis of 10 Case Series 2015 2 21 90%
Androgen Receptor Rediscovered: The New Biology and Targeting the Androgen Receptor Therapeutically 2011 96 36 69%
Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer 2015 2 51 82%
Second-line treatment options in metastatic castration-resistant prostate cancer: A comparison of key trials with recently approved agents 2014 12 15 80%
Optimal management of metastatic castration-resistant prostate cancer: Highlights from a European Expert Consensus Panel 2014 12 29 69%
Expanding Androgen- and Androgen Receptor Signaling-Directed Therapies for Castration-Resistant Prostate Cancer 2014 9 47 83%
Secondary hormonal therapy for advanced prostate cancer 2006 77 43 79%
Biomarkers in the Management and Treatment of Men with Metastatic Castration-Resistant Prostate Cancer 2012 50 69 52%
Targeting extra-gonadal androgens in castration-resistant prostate cancer 2015 2 56 61%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 PROSTATE CANC TARGETED THER Y GRP 27 78% 0.7% 18
2 LANK GENITOURINARY ONCOL 12 25% 1.6% 42
3 UROL ONCOL PROGRAM 7 32% 0.7% 19
4 GENITOURINARY ONCOL SERV 6 13% 1.7% 46
5 JOAN SANFORD E WEILL MED 6 58% 0.3% 7
6 TUMOR IMMUNOL BIOL 5 10% 1.7% 45
7 CAROLINA UROL 5 55% 0.2% 6
8 GENITOURINARY CANC SECT 4 39% 0.3% 9
9 DRUG DEV UNIT 4 15% 1.0% 26
10 GENITOURINARY MED ONCOL PROGRAM 4 75% 0.1% 3

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000149344 ANDROGEN DEPRIVATION THERAPY//INTERMITTENT ANDROGEN SUPPRESSION//BICALUTAMIDE
2 0.0000135534 EBP1//RADIOBIOL CANC//PA2G4
3 0.0000134510 ESTRAMUSTINE BINDING PROTEIN//ESTRAMUSTINE//ESTROMUSTINE
4 0.0000118688 ANDROGEN RECEPTOR//ANDROGEN INSENSITIVITY SYNDROME//ANDROGEN INSENSITIVITY
5 0.0000081244 UNIT IMMUNOMICROBIO ENVIRONM CARCINOGENESIS//ANTI INTERLEUKIN 6 ANTIBODY//AUTOCRINE AND PARACRINE LOOPS
6 0.0000073379 OSTEOBLASTIC METASTASIS//3 D COLLAGEN//AHTO 7
7 0.0000066921 RHENIUM 186 HEDP//BONE PAIN PALLIATION//STRONTIUM 89
8 0.0000057864 SURAMIN//HT 29 D4 CELLS//SURAMIN ANALOGUES
9 0.0000054043 PCA3//TMPRSS2 ERG//PROSTATE CANCER ANTIGEN 3
10 0.0000053227 MOL PATHOL ULTRASTRUCT//ENDOTHELIN AXIS//ZD4054